BR112013028735A2 - composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides - Google Patents

composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides

Info

Publication number
BR112013028735A2
BR112013028735A2 BR112013028735A BR112013028735A BR112013028735A2 BR 112013028735 A2 BR112013028735 A2 BR 112013028735A2 BR 112013028735 A BR112013028735 A BR 112013028735A BR 112013028735 A BR112013028735 A BR 112013028735A BR 112013028735 A2 BR112013028735 A2 BR 112013028735A2
Authority
BR
Brazil
Prior art keywords
steroids
steroidal anti
retaining members
inflammatory drugs
povidone iodine
Prior art date
Application number
BR112013028735A
Other languages
English (en)
Portuguese (pt)
Inventor
Liang Bo
Michael Samson C
Stein Jason
Capriotti Joseph
Weiser Michael
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013028735(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of BR112013028735A2 publication Critical patent/BR112013028735A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013028735A 2011-05-12 2012-05-11 composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides BR112013028735A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12
PCT/US2012/037563 WO2012155062A1 (en) 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories

Publications (1)

Publication Number Publication Date
BR112013028735A2 true BR112013028735A2 (pt) 2017-12-05

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028735A BR112013028735A2 (pt) 2011-05-12 2012-05-11 composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides

Country Status (16)

Country Link
US (1) US20150038473A1 (enExample)
EP (1) EP2707006B1 (enExample)
JP (2) JP6072009B2 (enExample)
KR (1) KR101967938B1 (enExample)
CN (1) CN103957922A (enExample)
AR (1) AR086399A1 (enExample)
AU (3) AU2012253335B2 (enExample)
BR (1) BR112013028735A2 (enExample)
CA (1) CA2835343A1 (enExample)
CL (1) CL2013003016A1 (enExample)
CO (1) CO6821949A2 (enExample)
EC (1) ECSP13013069A (enExample)
MX (1) MX360666B (enExample)
PE (1) PE20141070A1 (enExample)
TW (2) TWI717552B (enExample)
WO (1) WO2012155062A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP6226998B2 (ja) 2013-02-15 2017-11-08 千寿製薬株式会社 抗菌性金属を含有するジフルプレドナートエマルション組成物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
HK1248570A1 (zh) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
EP3416654B1 (en) 2016-02-18 2021-10-27 Invirsa, Inc. Medical use of 5'-adenosine diphosphate ribose (adpr)
US11040062B2 (en) 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
SG11201809811VA (en) * 2016-05-05 2018-12-28 Veloce Biopharma Llc Compositions and methods for treatment of inflammation or infection of the eye
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
EP4226971A1 (en) 2018-03-27 2023-08-16 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN113797162B (zh) * 2020-06-17 2023-05-05 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
US20240082188A1 (en) * 2021-01-21 2024-03-14 Taejoon Pharmaceutical Co., Ltd. Ophthalmic composition
EP4282432A4 (en) * 2021-01-22 2025-01-29 Chengdu Ruimu Biopharmaceuticals Co., Ltd. CARRIER OR AUXILIARY SUBSTANCE FOR OPHTHALMIC PREPARATION, ITS PREPARATION METHOD AND ITS APPLICATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) * 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
DK2291081T3 (da) * 2008-06-12 2020-08-10 Foresight Biotherapeutics Inc Povidon-iod, et nyt alternativt konserveringsmiddel til ophthalmiske sammensætninger
JP2013514373A (ja) * 2009-12-15 2013-04-25 フォーサイト・バイオセラピューティクス・インコーポレーテッド 非刺激性の眼科用ポビドンヨード組成物
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物

Also Published As

Publication number Publication date
JP6359619B2 (ja) 2018-07-18
AR086399A1 (es) 2013-12-11
KR20140045375A (ko) 2014-04-16
US20150038473A1 (en) 2015-02-05
TW201811340A (zh) 2018-04-01
CL2013003016A1 (es) 2014-05-02
EP2707006A4 (en) 2014-09-24
TWI632914B (zh) 2018-08-21
AU2012253335A1 (en) 2013-05-02
ECSP13013069A (es) 2015-03-31
JP2014516954A (ja) 2014-07-17
KR101967938B1 (ko) 2019-04-10
MX2013012971A (es) 2013-12-12
EP2707006B1 (en) 2019-07-03
PE20141070A1 (es) 2014-09-14
AU2018203492A1 (en) 2018-06-07
CO6821949A2 (es) 2013-12-31
AU2016222491A1 (en) 2016-09-22
JP6072009B2 (ja) 2017-02-01
TWI717552B (zh) 2021-02-01
WO2012155062A1 (en) 2012-11-15
AU2012253335B2 (en) 2016-08-04
TW201311256A (zh) 2013-03-16
EP2707006A1 (en) 2014-03-19
JP2017095474A (ja) 2017-06-01
CA2835343A1 (en) 2012-11-15
CN103957922A (zh) 2014-07-30
MX360666B (es) 2018-11-13

Similar Documents

Publication Publication Date Title
BR112013028735A2 (pt) composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides
BR112013009496B8 (pt) Sistemas de artigos absorventes
LT3727242T (lt) Ostomijos sistemos monitoriaus prietaisas, turintis jungtį, skirtą prijungimui tiek prie pagrindinės plokštės tiek prie pagalbinio įtaiso
BR112015011946A2 (pt) dispositivo de conexão
BR112012012028A2 (pt) dispositivo telescópico
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
BR112015025299A2 (pt) sistema cirúrgico com envoltórios estéries
BR112015020509A2 (pt) elemento de fechamento de garra para atuador de extremidade de um instrumento cirúrgico
EP2857837A4 (en) LYOPHILIZATION CONJUGATE CONSTRUCT FOR IMMUNCHROMATOGRAPHIC POC TESTS, KIT FOR IMMUNESTEST THEREOF AND METHOD FOR ANALYSIS WITH THE TEST KIT
BR112017004318A2 (pt) sistema de fixação externa para um exoesqueleto ortopédico
BR112014028248A2 (pt) ligação de plugue para linhas de fluido e parte de retenção para uma ligação de plugue desse tipo
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
BR102012024461A8 (pt) Abraçadeira para fixação de tubos
HRP20191489T1 (hr) Kombinirani sastav
BR112015021179A2 (pt) composições farmacêuticas com melhor desempenho e melhor processabilidade
BR112015003433A2 (pt) dispositivos de fixação espinhal pivotantes
BR112015026634A2 (pt) sistema de motor de foguete orientável
BR112016006149A2 (pt) rosca de conexão para um sistema de maçarico
BR112014029143A2 (pt) mecanismo de liberação térmica para ferramentas de fundo do poço
BR112015029465A2 (pt) dispositivo de cuidados pessoais como um dispositivo de barbeamento ou depilação, estrutura de cabeça para uso em um dispositivo de cuidados pessoais como um dispositivo de barbeamento ou depilação, estrutura de base para uso em um dispositivo de cuidados pessoais como um dispositivo de barbeamento ou depilação, e, estrutura de acoplamento
BR112014008400A2 (pt) derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
BR112013026565A2 (pt) dispositivo pivotável de conexão tripla de tamanho ajustável
BR112015032211A2 (pt) Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f
BR112013028737A2 (pt) dispositivo de bloqueio
EP2914580A4 (en) THIOARYL DERIVATIVES AS GPR120 AGONISTS

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/485,475 DE 12/05/2011 REIVINDICADA NO PCT/US2012/037563, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("FORESIGHT BIOTHERAPEUTICS, INC") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO FOI APRESENTADO O DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPIPR 179/2017.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B12F Other appeals [chapter 12.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09B Patent application refused [chapter 9.2 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: FORESIGHT BIOTHERAPEUTICS, INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2648 DE 05/10/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL